All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the challenges and possibilities of ctDNA to monitor response and relapse in MM?

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Parameswaran Hari, Medical College of Wisconsin, Milwaukee, US. We asked, What are the challenges and possibilities of circulating tumor DNA (ctDNA) to monitor response and relapse in MM?

What are the challenges and possibilities of ctDNA to monitor response and relapse in MM?

Using ctDNA to detect minimal residual disease (MRD) in the peripheral blood presents a sensitive, noninvasive technique to predict relapse in patients with multiple myeloma (MM). Hari outlines the advantages of ctDNA analysis over bone marrow aspiration, and presents data from a study investigating the prognostic value of ctDNA in patients with MM following auto-HCT.

Share: